Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


@@#116300@@

European Psychiatry
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le samedi 11 juin 2011
Doi : 10.1016/j.eurpsy.2011.03.006
Received : 13 December 2010 ;  accepted : 29 Mars 2011
Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder
 

Y. Levkovitz a, ⁎, b , J.E. Alpert b, C.E. Brintz b, D. Mischoulon b, G.I. Papakostas b
a Psychiatry Department, Shalvata Mental Health Center, Tel Aviv University, Hamargoa 4, POB 94, Tel Aviv, Israel 
b The Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15, Parkman Street, Boston, MA 02114, USA 

Corresponding author. Tel.: +972 9 7478644; fax: +972 9 7478643.
Abstract

Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosylmethionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD.

Objectives

This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD.

Methods

Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment.

Results

There was a greater improvement in the ability to recall information (P =0.04) and a trend towards statistical significance for greater improvement in word-finding (P =0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance.

Conclusions

These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.


Keywords : Pharmacotherapy, Major depression, S-adenosylmethionine, Cognitive function, One-carbon cycle


OutlineMasquer le plan
Introduction
Methods  (+)
Results
Discussion
Conclusion
Disclosure of interest


© 2011  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline